Phase II trial of RX 0201 given in combination with carboplatin and paclitaxel as second-line therapy in patients with platinum-sensitive ovarian cancer.
Phase of Trial: Phase II
Latest Information Update: 14 May 2012
At a glance
- Drugs RX 0201 (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Therapeutic Use
- 14 May 2012 New trial record
- 08 May 2012 A phase II trial protocol has been submitted to the US FDA, according to a Rexahn Pharmaceuticals media release.